Nobu Ueki Is Looking for Cancer's Off Switch

The Chicago scientist built a career around a stubborn question: can a drug wait until a cancer cell gives it permission to act? His answer spans two molecular locks, one active US patent, and a startup betting on the peculiar weakness of cells in transit.